As an innovative leader in the development of plant-based vaccines, Medicago’s unique platform allows us to quickly respond to global health emergencies.
We can respond rapidly, first by producing a matching virus-like particles (VLP) to a virus strain in 20 days or less, then by generating a candidate vaccine and then testing it for quality, safety and efficacy. The safety, efficacy and quality of our vaccine candidates are at the forefront of the work we do every day.
We are continuously working to help meet the growing needs of public health around the world and it is through our research and development of several vaccine candidates that we hope to provide solutions to help protect public health.
Producing of virus-like particles (VLPs), 20 days after obtaining the gene sequence was the first step in developing a vaccine for COVID-19, before starting preclinical and clinical testing for safety, efficacy and quality.
Disclaimer: This vaccine is not approved for use in humans.
Evidence shows that Medicago’s plant-based quadrivalent and adjuvanted virus-like particle (VLP) influenza vaccine candidate has the potential to induce antibody production and a cell-mediated immune response.
Disclaimer: This vaccine is not approved for use in humans.
Norovirus is a highly contagious virus and Medicago has launched a pre-clinical study to develop a vaccine candidate.
Disclaimer: This vaccine is not approved for use in humans.
A pandemic influenza is an influenza virus epidemic that spreads globally and infects a large portion of the world’s population. Unlike regular seasonal flu epidemics, influenza pandemics are rare.
Disclaimer: This vaccine is not approved for use in humans.
In partnership with Mitsubishi Tanabe Pharma Corporation, Medicago is developing a rotavirus-like particle vaccine candidate to combat this scourge. Its vaccine candidate is currently undergoing Phase 1 studies.
Disclaimer: This vaccine is not approved for use in humans.
